Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd.
Your view on CGNSF
Overview
What the company does, where it operates, and who runs it.
About Cognetivity Neurosciences Ltd.
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Sina Habibi
- Headquarters
- 1055 West Hastings Street, Vancouver, BC, CA
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Sina Habibi
- Headquarters
- 1055 West Hastings Street, Vancouver, BC, CA
Cognetivity Neurosciences Ltd. operates as a healthcare company.
It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app.
The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cognetivity Neurosciences Ltd., and the rating behind it. CGNSF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cognetivity Neurosciences Ltd.. Starting points for Cognetivity Neurosciences Ltd.: EPS -$0.08, beta 0.84 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cognetivity Neurosciences Ltd.. Cognetivity Neurosciences Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cognetivity Neurosciences Ltd.. Trailing twelve-month EPS for Cognetivity Neurosciences Ltd. stands at -$0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cognetivity Neurosciences Ltd.. Cognetivity Neurosciences Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cognetivity Neurosciences Ltd. valued side by side against its closest peers. Cognetivity Neurosciences Ltd. is measured against Medical - Healthcare Information Services peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cognetivity Neurosciences Ltd., and how their positions are changing. At a $8,959 market value, institutional positions materially move Cognetivity Neurosciences Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cognetivity Neurosciences Ltd. executives and directors. Shares of Cognetivity Neurosciences Ltd. have traded between $0.0001 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cognetivity Neurosciences Ltd.. Cognetivity Neurosciences Ltd. is a $8,959 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cognetivity Neurosciences Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cognetivity Neurosciences Ltd.. Coverage tracks Cognetivity Neurosciences Ltd. within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.